Clinical characteristics of non-perianal fistulating Crohn's disease in China: A single-center experience of 184 cases

Chinese Medical Journal

Volumn 125, Issue 14, 2012, Pages 2405-2410

  Wang, Ge Fei ^a   Ren, Jian An ^a   Liu, Song ^a   Chen, Jun ^a   Gu, Guo Sheng ^a   Wang, Xin Bo ^a   Fan, Chao Gang ^a   Li, Jie Shou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Clinical feature; Crohn's disease; Follow up; Inflammatory bowel disease; Non perianal fistulae

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZATHIOPRINE; BETA LACTAM ANTIBIOTIC; CORTICOSTEROID; CYCLOSPORIN A; FLUCONAZOLE; MESALAZINE; METRONIDAZOLE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHILD; CHINA; CLINICAL FEATURE; CROHN DISEASE; DEATH; DIARRHEA; ENTERIC FEEDING; FEMALE; FEVER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON PERIANAL FISTULATING CROHN DISEASE; PARENTERAL NUTRITION; RETROSPECTIVE STUDY; SMALL INTESTINE; SURVIVAL;

ADOLESCENT; ADULT; CHINA; CROHN DISEASE; DRUGS, CHINESE HERBAL; FEMALE; GLYCOSIDES; HUMANS; MALE; MIDDLE AGED; RECTAL FISTULA; TRIPTERYGIUM; YOUNG ADULT;

EID: 84864224893     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.14.001     Document Type: Article

References (22)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
2. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55: i36-i58.
3. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101.
4. Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112-124.
5. Ye BD, Yang SK, Cho YK, Park SH, Yang DH, Yoon SM, et al. Clinical features and long-term prognosis of Crohn's disease in Korea. Scand J Gastroenterol 2010; 45: 1178-1185.
6. Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000; 43: S85-S93.
7. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101: 1274-1282.
8. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006; 101: 1559-1568.
9. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis 2004; 10: 646-651.
10. Zheng JJ, Shi XH, Chu XQ, Jia LM, Wang FM. Clinical features and management of Crohn's disease in Chinese patients. Chin Med J 2004; 117: 183-188.
11. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38-45.
12. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002; 46: 1735-1743.
13. Tao QS, Ren JA, Li JS. Triptolide suppresses IL-1beta-induced chemokine and stromelysin-1 gene expression in human colonic subepithelial myofibroblasts. Acta Pharmacol Sin 2007; 28: 81-88.
14. Ren J, Tao Q, Wang X, Wang Z, Li J. Efficacy of T2 in active Crohn's disease: a prospective study report. Dig Dis Sci 2007; 52: 1790-1797.
15. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274: 13443-13450.
16. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007: CD000542.
17. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55: i16-i35.
18. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4: 28-62.
19. Wilcox AR, Dragnev MC, Darcey CJ, Siegel CA. A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match? Inflamm Bowel Dis 2010; 16: 645-650.
20. Prantera C, Berto E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998; 30: 602-606.
21. Oriuchi T, Hiwatashi N, Kinouchi Y, Takahashi S, Takagi S, Negoro K, et al. Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality. J Gastroenterol 2003; 38: 942-953.
22. Du RY, Li SD, Huang CT, Guo QX, Shi WM. Long-term results in surgical treatment of Crohn's disease. Chin Med J 1984; 97: 317-321.